Attorney Reference Number 5585-71231-01
Application Number 10 / 538465

JC17 Rec'd PCT/PTO 10 JUN 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): An adjuvant comprising an isolated conjugate of a CD28 and/or CD40 antibody and at least one antigen wherein said conjugate consists of an oligomeric complex wherein the antibody valency of the complex does not exceed an average of about five antibody molecules per complex.

Claim 2 (currently amended): An adjuvant according to Claim 1, wherein said conjugate consists of an average of one to four antibody molecules per complex.

Claim 3 (currently amended): An adjuvant according to Claim 2, wherein said complex consists of an average of one to three antibody molecules per complex.

Claim 4 (currently amended): An adjuvant according to Claim 1 2 or 3, wherein said complex consists of one to two antibody molecules per complex.

Claims 5-8 (canceled).

Claim 9 (currently amended): An adjuvant according to <u>Claim 1</u> any of <u>Claims 1-4</u>, wherein said antigen is a T-cell dependent antigen.

Claim 10 (currently amended): An adjuvant according to <u>Claim 1</u> any of <u>Claims 1-4</u>, wherein said antigen is a T- cell independent antigen.

Claim 11 (currently amended): An adjuvant according to <u>Claim 1</u> Claim 9 or 10, wherein said antigen is derived from a pathogenic bacterium.

Claim 12 (original): An adjuvant according to Claim 11, wherein said antigen is derived from a bacterial species selected from the group consisting of: Staphylococcus aureus; Staphylococcus epidermidis; Enterococcus faecalis; Mycobacterium tuberculsis; Streptococcus group B; Streptococcus pneumoniae; Helicobacter pylori; Neisseria gonorrhea; Streptococcus group A; Borrelia burgdorferi; Coccidiodes immitis; Histoplasma sapsulatum; Neisseria meningitidis; Shigella flexneri; Escherichia coli; Haemophilus influenzae.

Claim 13 (currently amended): An adjuvant according to <u>Claim 1</u> Claim 9 or 10, wherein said antigen is derived from a viral pathogen.

Claim 14 (currently amended): An adjuvant according to Claim 13, wherein said antigen is derived from a viral pathogen from selected from the group consisting of: Human Immunodeficiency Virus, (HIV1 & 2); Human T Cell Leukaemia Virus, (HTLV 1 & 2); Ebola virus[[;]], human papilloma virus, (e.g. HPV 2, HPV 5, HPV 8 HPV 16, HPV 18, HPV 31, HPV 33, HPV 52, HPV 54 and HPV 56); papovavirus[[;]], rhinovirus[[;]], poliovirus[[;]], herpesvirus[[;]], adenovirus[[;]], Epstein Barr virus[[;]], influenza virus, hepatitis B virus or and hepatitis C virus viruses.

Claim 15 (currently amended): An adjuvant according to Claim 1 Claim 9 or 10, wherein said antigen is derived from a parasitic pathogen.

Claim 16 (currently amended): An adjuvant according to Claim 15, wherein said antigen is derived a parasistic parasitic pathogen selected from the group consisting of: *Trypanosoma spp*, Schistosoma spp or Plasmodium spp.

Claim 17 (currently amended): An adjuvant according to <u>Claim 1</u> Claim 9 or 10, wherein said antigen is derived from a fungal pathogen.

Page 5 of 8

Claim 18 (currently amended): An adjuvant according to Claim 17, wherein said antigen is derived from a fungal pathogen which is of the genus *Candida spp*.

Claim 19 (currently amended): An adjuvant according to <u>Claim 1</u> Claim 9 or 10, wherein said antigen is a tumour specific antigen or a tumour associated antigen.

Claim 20 (original): An adjuvant according to Claim 19, wherein said antigen is a ganglioside antigen.

Claim 21 (currently amended): An adjuvant according to Claim 19 or 20, wherein said antigen is MUC-1.

Claim 22 (currently amended): An adjuvant according to <u>Claim 1</u> Claim 9 or 10, wherein said antigen is a hormone or hormone receptor.

Claim 23 (original): An adjuvant according to Claim 22, wherein said antigen is the N-methyl-D aspartate receptor, or part thereof.

Claim 24 (currently amended): An adjuvant according to <u>Claim 1</u> Claim 9 or 10, wherein said antigen is a prion protein.

Claim 25 (original): An adjuvant according to Claim 24, wherein said antigen is an amyloid protein.

Claim 26 (currently amended): An adjuvant according to Claim 25, wherein wherein said antigen is amyloid β or part thereof.

Claim 27 (currently amended): An adjuvant according to Claim 1 Claim 9 or 10, wherein said antigen is a sperm antigen.

Claim 28 (currently amended): An adjuvant according to Claim 1 Claim 9 or 10, wherein said antigen is an addictive drug.

Claim 29 (currently amended): An adjuvant according to Claim 28, wherein said drug is selected from the group consisting of[[:]] cocaine[[;]], nicotine[[;]], [[or]] and heroin.

Claims 30-50 (canceled).

Page 7 of 8